Patent classifications
A61L27/22
Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.
Coacervate composition containing protein drug and wound healing agent comprising same
The present disclosure provides a coacervate composition containing a protein drug, gelatin A, sodium alginate and an acid and a wound-healing agent including the same. The coacervate composition according to the present disclosure can be useful as a wound-healing material delivery system for effectively delivering a protein drug, particularly epidermal growth factor, to a wound site in the wound-healing field.
METHOD FOR INDUCING GELATION AND BIOMIMETIC MINERALIZATION OF SILK FIBROIN SOLUTION BY ALKALINE PHOSPHATASE
The invention provides a method for inducing gelation and biomimetic mineralization of a silk fibroin solution by alkaline phosphatase. A micromolecular polypeptide that is sensitive to ALP and has good biocompatibility and self-assembly property is introduced as a gelator precursor, which can remove a phosphate group under the catalytic action of ALP to generate NY, to trigger supramolecular self-assembly, and therefore SF co-self-assembly is synergistically induced, finally resulting in rapid formation of SF hydrogel. ALP wrapped in an SF-NY hydrogel network still retains its catalytic activity and catalyzes beta-glycerophosphate to release free phosphate ions, so that formation of apatite minerals is induced in the gel. The biomimetic mineralized SF gel can be used as a biomimetic scaffold to promote the adhesion, proliferation and osteogenic differentiation of rat bone marrow mesenchymal stem cells in vitro, and can also promote the natural healing of femoral defects in a rat model.
Method for supplying inks for three-dimensional printing, and three-dimensional printing method using same
The present invention relates to a method of filling different two-kinds of multiple inks into an ink extruding member for a three-dimensional print and a method of three-dimensional printing using the filled ink, and relates to a three-dimensional printing method using multiple inks comprising a step of applying pressure to the retained multiple inks and extruding it into a single extruding port of the extruding part to prepare an ink extruded product and printing the ink extruded product.
Sterilization of self-assembling peptides by irradiation
Gamma ray and e-beam irradiation provided efficient sterilization of certain self-assembling peptides (including RADA16 in solution) without substantial degradation of the major peptide, while, e.g., another self-assembly peptide, QLEL12 was significantly degraded following irradiation. Irradiation sterilization enhances the rheological property of, for example, RADA16 hydrogel once applied to tissue at a physiological pH. The rheological property increase can result in higher efficacy in a variety of biomedical applications.
LIQUID COMPOSITION AND POROUS HARDENED MATERIAL COMPRISING TETRAFLUOROETHYLENE AND VINYL MOIETY CO-POLYMERS
A porous hardened material is provided for various medical applications, including strengthening, supporting, moving, reinforcing, separating, isolating, and/or bulking biological substrates. The hardened material is formed from a liquid composition including a fluorinated copolymer and a biocompatible solvent system. The fluorinated copolymer includes a tetrafluoroethylene (TFE) moiety and a vinyl moiety, wherein the vinyl moiety comprises at least one functional group selected from acetate, alcohol, amine, and amide.
LIQUID COMPOSITION AND POROUS HARDENED MATERIAL COMPRISING TETRAFLUOROETHYLENE AND VINYL MOIETY CO-POLYMERS
A porous hardened material is provided for various medical applications, including strengthening, supporting, moving, reinforcing, separating, isolating, and/or bulking biological substrates. The hardened material is formed from a liquid composition including a fluorinated copolymer and a biocompatible solvent system. The fluorinated copolymer includes a tetrafluoroethylene (TFE) moiety and a vinyl moiety, wherein the vinyl moiety comprises at least one functional group selected from acetate, alcohol, amine, and amide.
Nonwoven Fabric Containing Silk Fibers, Wound Dressing, iPS Cell Scaffold Material, Nonwoven Fabric for Blood-Compatible Material, Blood-Compatible Material, Production Method of Nonwoven Fabric Containing Silk Fibers, Production Method of Wound Dressing, Production Method of iPS Cell Scaffold Material, Production Method of Non-Woven Fabric for Blood-Compatible Material, and Production Method of Blood-Compatible Material
One embodiment of the present invention provides a nonwoven fabric containing silk fibers in which an abs intensity ratio [abs (1650)/abs (1620)], which is a ratio of an intensity of a peak positioned in a vicinity of 1650 cm.sup.−1 [abs (1650)] in an infrared absorption spectrum to an intensity of a peak positioned in a vicinity of 1620 cm.sup.−1 [abs (1620)] in an infrared absorption spectrum, is larger than 0.65 and 1.90 or less, and a method for producing the nonwoven fabric containing silk fibers.
PROTEIN-BASED BIOMATERIAL WITH VISCOELASTIC BEHAVIOUR, PROCESS FOR OBTAINING IT AND USES THEREOF
The present invention relates to a process of preparation of a biomaterial comprising the steps of: a) Preparing a solution comprising at least one protein having a solubility in water superior or equal to about 10 mg/mL and at least one salt having solubility in water superior or equal to about 500 mg/mL, b) Evaporating the solution obtained in step a) as is, as a foam obtained by foaming the solution obtained in step a), or as a mixture thereof, at a temperature comprised of from 4 to 50° C. in atmospheric pressure or at lower temperatures under vacuum or at a pressure lower than atmospheric pressure, until the formation of two non-miscible phases or until obtaining a substantially dry solid, thereby obtaining a biomaterial.
The present invention also relates to a biomaterial obtainable by the process, and to the use of the biomaterial as a support for in vitro tissue engineering and/or for in vitro cell culture and in vitro expansion and/or as an implantable medical device, or as a drug.
USE OF FUNCTIONALIZED AND NON-FUNCTIONALIZED ECMS, ECM FRAGMENTS, PEPTIDES AND BIOACTIVE COMPONENTS TO CREATE CELL ADHESIVE 3D PRINTED OBJECTS
Embodiments of this disclosure relate to bioinks and bioink compositions. These bioinks may be 3D printed into a hydrogel. The printed hydrogel may support primary cell and induced pluripotent stem cell attachment, proliferation, and spreading. Compounds in the bioink may be modified to incorporate chemical functionality, such as by chemical synthesis means. Incorporating chemical functionality may allow the incorporation of modified material as a component in the bioink. The modifications may allow chemical conjugation of a desired component. The desired component may maintain its cell interactive feature to aid in cell attachment and proliferation. Such incorporation may allow modulation of the bioprinted object's mechanical properties without interfering with cell adhesion.